Centre Medico Chirurgical Ambroise Pare Hartmann — Clinical Trial Site

54 Registered trials

24 Currently recruiting

Organisation

Centre Medico Chirurgical Ambroise Pare Hartmann

Location

Neuilly-Sur-Seine, France

Identifier

ORG-100046315

Address

48 Ter Boulevard Victor Hugo, 92200, France

Departments

/
#6002: Intensive Care Unit
Cardiology
Centre satellite
Chirurgie cardiaque et interventionnelle
CLINIQUES AMBROISE PARE
FR10003: Institut des MICI
FR10008: Institut des MICI
Gastro-entérologie
GASTRO-ENTEROLOGIE ET HEPATOLOGIE
GASTROENTEROLOGIE
gastroenterology
Hépato-Gastro-Entérologie
Hepato-gastro-enterology
Institut des MICI
Intensive care
Intensive care medicine
lnstitut des MICI
maladies inflammatoires chroniques de l’intestin
Medical Oncology
Oncologie medicale
Oncology
Radiation Oncology
Réanimation
Service d’oncologie

Clinical trials at this site (54)

Search interface

A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown

2025-523766-25-00 Ulcerative colitis 5
Corticoid Therapy in Acute Myocarditis Pending

2024-510602-90-00 Patients presenting with acute myocarditis proven by ca 5
Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled tr… Pending

2024-514633-38-00 Crohn’s Disease 5
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending

2025-521590-13-00 Moderately to Severely Active Crohn’s Disease 5
OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE Pending

2025-524573-16-00 Crohn's disease 6
A Multi-Stage Study to Test a New Drug in Healthy Adult Volunteers, Then in Adults with Ulcerative Colitis Recruiting

2025-522702-21-00 Ulcerative Colitis is a type of inflammatory bowel dise 4 2026-01-26
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Crohn’s Disease 5 2025-09-29
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe… Recruiting

2024-520209-38-00 Obesity or Overweight 5 2025-09-19
A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn'… Recruiting

2024-513054-30-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a… Recruiting

2023-509606-30-00 Ulcerative colitis 5 2024-07-24
A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c… Recruiting

2023-504265-23-00 Crohn's disease 4 2023-10-23
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
A Study to Assess the Efficacy, Safety, and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Co… Recruiting

2025-520690-39-00 Moderately to Severely Active Ulcerative Colitis (UC) 4 2025-11-04
Prophylactic Anti-aRrhythmic therapy with Amiodarone in critically ill patients admitted for an out-of-hospital Cardiac Arrest with initial … Recruiting

2023-510099-30-00 Out-of-hospital cardiac arrest with initial shockable r 5 2025-09-23
A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC Recruiting

2024-520386-31-00 Locally Advanced Head & Neck Squamous Cell Carcinoma 5 2025-09-22
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight:… Recruiting

2024-520210-21-00 Crohn’s Disease 5 2025-09-19
Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo… Recruiting

2024-515349-41-00 Metastatic Breast Cancer HR+, HER2- 4 2025-07-29
EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting

2023-506817-23-01 Metastatic hormone naïve prostate cancer (mHNPC) 5 2025-05-23
A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti… Recruiting

2024-513053-69-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
A clinical study of tulisokibart in people with Crohn’s disease or ulcerative colitis (MK-7240-011) Recruiting

2024-513533-20-00 Crohn’s Disease or Ulcerative Colitis 5 2025-02-25
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting

2023-508234-34-00 Crohn's disease 4 2025-01-27
A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting

2023-506704-14-00 Moderately to Severely Active Crohn's Disease 4 2024-09-04
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
FFCD 2006 – NEORAF : A MULTI-CENTRE, OPEN-LABEL, PILOT TRIAL EVALUATING THE COMBINATION ENCORAFENIB AND CETUXIMAB IN A NEOADJUVANT SETTING I… Recruiting

2024-514107-34-00 BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANC 4 2024-07-18